Australian doctors warn of malnutrition risk with GLP-1 weight drugs
University of Newcastle research reveals a critical gap in tracking malnutrition and muscle loss in people taking GLP-1 weight-loss drugs.
Experts warn that millions of Australians taking GLP-1 drugs like Ozempic, Wegovy and Mounjaro risk malnutrition and muscle loss. But these risks are not being tracked.
Professor Clare Collins reviewed studies on about 50,000 adults using GLP-1s. She found a major gap in evidence about the danger.
When people eat far less, they may not get enough protein to protect their muscles. They also miss vitamins and minerals needed for healing, energy and brain function.
Severe cases can cause brain damage, heart problems or death. Side effects like fatigue and nausea look like nutrient deficiency symptoms and are easily missed.
Experts say people need regular check-ups, more protein, strength training, and possibly supplements.
- About 50,000 adults studied
- Research scope
- Brain damage, heart problems and death
- Risk in severe cases
- University of Newcastle
- Institution
Why it mattersIf malnutrition goes unnoticed in GLP-1 users, it could cause serious long-term damage that could have been prevented with simple dietary changes.
AustraliaAustralian GPs and patients starting GLP-1s need to understand malnutrition risk and work with dietitians to prevent muscle loss and nutrient deficiencies.
Corroborated bytheage.com.au
